Related Experiment Video
Updated: May 8, 2026
12:21
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding
Brahmaraju Mopidevi1, Madhusudhan Ponnala, Ashok Kumar
1Department of Physiology and Pharmacology, University of Toledo Health Science Campus, Toledo, Ohio.
Physiological Genomics
|August 15, 2013
Summary
MicroRNAs miR-31 and miR-584 target the Angiotensinogen (AGT) gene, potentially offering a new therapeutic strategy for hypertension. These findings link genetic factors to blood pressure regulation.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Disease Research
Background:
- Hypertension is a major cardiovascular disease risk factor, influenced by genetic and environmental factors.
- The renin-angiotensin system, particularly the Angiotensinogen (AGT) gene, is crucial in blood pressure regulation.
- A specific polymorphism (rs7079) in the human AGT 3'-untranslated region (3'-UTR) is linked to elevated blood pressure.
Purpose of the Study:
- To investigate the interaction between specific microRNAs (miRNAs) and the human AGT 3'-UTR.
- To determine if miR-31 and miR-584 influence AGT gene expression.
- To explore potential novel therapeutic targets for hypertension based on miRNA-gene interactions.
Main Methods:
- Analysis of miR-31 and miR-584 binding affinity to the hAGT 3'-UTR with different alleles (11525C vs. 11525A).
- Transfection experiments in human liver cells to assess the impact of miR-31 and miR-584 on AGT mRNA and protein levels.
Main Results:
- miR-31 and miR-584 demonstrated stronger binding to the 11525C allele of the hAGT 3'-UTR compared to the 11525A allele.
- Transfection with miR-31 and miR-584 led to a significant downregulation of both AGT mRNA and protein in human liver cells.
Conclusions:
- Specific miRNAs, miR-31 and miR-584, directly regulate the expression of the Angiotensinogen (AGT) gene.
- These findings suggest a novel mechanism involving miRNA-mediated control of the renin-angiotensin system.
- Targeting these miRNA-AGT interactions could represent a new therapeutic avenue for managing hypertension.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...